Living donor liver transplantation for hepatocellular carcinoma: The impact of neo-adjuvant treatments on the long term results

Hepato-Gastroenterology

Volumn 59, Issue 114, 2012, Pages 505-510

  Di Sandro, Stefano ^a,b   Giacomoni, Alessandro ^a   Slim, Abdallah ^a   Lauterio, Andrea ^a   Mangoni, Iacopo ^a   Mihaylov, Plamen ^a,b   Pirotta, Vincenzo ^a   Aseni, Paolo ^a   De Carlis, Luciano ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Hepatocellular carcinoma; Living donor liver transplantation; Pre transplant treatments

Indexed keywords

ALPHA FETOPROTEIN; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DECEASED DONOR LIVER TRANSPLANTATION; GRAFT REJECTION; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; LIVING DONOR; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS ALCOHOLIZATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; TRANSPLANTATION;

CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVING DONORS; LOGISTIC MODELS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 84860597357     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11225     Document Type: Article

References (28)

1. Roayaie S, Frischer JS, Emre SH, et al.: Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235(4):533-9. (Pubitemid 34258353)
2. Yao FY, Bass NM, Nikolai B, et al.: A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003; 9(7):684-92. (Pubitemid 36874454)
3. Llovet JM, Bru' C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329-338.
4. Bharat A, Brown DB, Crippin JS, et al.: Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve long term survival. J Am Coll Surg 2006; 203(4):411-20. (Pubitemid 44416253)
5. Yao FY, Kinkhabwala M, LaBerge JM, et al.: The impact of preoperative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant 2005; 5(4 Pt 1):795-804. (Pubitemid 40461290)
6. Roayaie S, Frischer JS, Emre SH, et al.: Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235(4):533-9. (Pubitemid 34258353)
7. Harnois DM, Steers J, Andrews JC, et al.: Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver Transpl Surg 1999; 5:192-199. (Pubitemid 29217989)
8. Venook AP, Ferrell LD, Roberts JP, et al.: Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization. Liver Transpl Surg 1995; 1:242-248.
9. Fisher RA, Maluf D, Cotterell AH, et al.: Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplantation waiting list. Clin Transplant 2004; 18:502-512. (Pubitemid 39264345)
10. Fontana RJ, Hamidullah H, Nghiem H, et al.: Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl 2002; 8:1165-1174. (Pubitemid 35469879)
11. Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334(11):693-9. (Pubitemid 26079803)
12. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S: Is the pathologic TNM Staging system for patients with hepatoma predictive of outcome? Cancer 2000; 88(3):538-43. (Pubitemid 30056926)
13. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP: Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8(9):765-74. (Pubitemid 35012284)
14. Yao FY, Ferrell L, Bass NM, et al.: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33(6):1394-403. (Pubitemid 32496976)
15. Kaihara S, Kiuchi T, Ueda M, et al.: Living-donor liver transplantation for hepatocellular carcinoma. Transplantation 2003; 75(3):S37-40. (Pubitemid 36222987)
16. Lewin M, Mourra N, Honigman I, Fléjou JF, Parc R, Arrivé L, Tubiana JM: Assessment of MRI and MRCP in diagnosis of biliary cystadenoma and cystadenocarcinoma. Eur Radiol 2006; 16(2):407-13. (Pubitemid 43149639)
17. Foster JH, Berman MM: The malignant transformation of liver cell adenomas. Arch Surg 1994; 129(7):712-7. (Pubitemid 24208713)
18. Todo S, Furukawa H: Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004; 240:451-459; discussion 459-461.
19. Gondolesi GE, Roayaie S, Munoz L, et al.: Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004; 239:142-149. (Pubitemid 38176346)
20. Malagó M, Sotiropoulos GC, Nadalin S, et al.: Living donor liver transplantation for hepatocellular carcinoma: a single-center preliminary report Liver Transpl 2006; 12(6):934-40. (Pubitemid 43960369)
21. Fisher RA, Kulik LM, Freise CE, et al.: Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007; 7:1601-1608. (Pubitemid 46776250)
22. Yang ZF, Poon RT, Luo Y, et al.: Up-regulation of vascular endothelial growth factor (VEGF) in small-for-size liver grafts enhances macrophage activities through VEGF receptor 2-dependent pathway. J Immunol 2004; 173:2507-2515. (Pubitemid 39063109)
23. Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J: Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 2007; 94:78-86. (Pubitemid 46142736)
24. Lee SG, Hwang S, Moon DB, et al.: Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008; 14:935-945. (Pubitemid 352003892)
25. Concejero A, Chen CL, Wang CC, et al.: Living donor liver transplantation for hepatocellular carcinoma: a single-center experience in Taiwan. Transplantation 2008; 85:398-406. (Pubitemid 351322764)
26. Vakili K, Pomposelli JJ, Cheah YL, et al.: Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Liver Transpl 2009; 15(12):1861-6.
27. Taketomi A, Sanefuji K, Soejima Y, et al.: Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009; 87(4):531-7.
28. de Haas RJ, Adam R, Wicherts DA, et al.: Comparison of simultaneous or delayed liver surgery for limited synchronous colorectal metastases. Br J Surg 2010; 97:1279-1289.